Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer

Journal of Surgical Oncology

Volumn 94, Issue 4, 2006, Pages 316-324

  Rufián, Sebastián ^a   Muñoz Casares, Francisco C ^a   Briceño, Javier ^a   Díaz, Carlos J ^a   Rubio, María J ^a   Ortega, Rosa ^a   Ciria, Rubén ^a   Morillo, Manuel ^a   Aranda, Enrique ^a   Muntané, Jordi ^a   Pera, Carlos ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Hyperthermia; Intraperitoneal chemotherapy; Peritonectomy

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTHERMIC INTRAOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; LYMPH NODE; OVARY CANCER; PERITONECTOMY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; SURGICAL TECHNIQUE;

ADULT; AGED; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INTRAOPERATIVE CARE; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PERITONEUM; PROGNOSIS; SURVIVAL RATE;

EID: 33748333113     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20597     Document Type: Article

References (32)

1. Rey Y, Porcheron J, Talabard JN, et al.: Carcinoses pé ritonéales traitées par chirurgie de réduction tumorale et chimiohyperthermie intrapéritonéale. Ann Chir 2000;125:631-642.
2. Shimizu Y, Tatsuki Y, Fujimoto I, et al.: Multimodal treatment for avanced, ovarian cancer patients with poor performance status-its effectiveness and limitations. Nippon Sanka Fujinka Gakkai Zasshi 1992;44:1551-1558.
3. Jahne J, Piso P: Peritonectomy and intraperitoneal chemotherapy-new methods in multi-modality therapy of peritoneal carcinosis. Langenbecks Arch Chir Suppl Kongressbd 1998;15:1435-1437.
4. Tournigand C, Louvert C, Molitor JL, et al.: Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma. Gynecol Oncol 2001;83:198-204.
5. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
6. Poveda A: Ovarian cancer treatment: What is new. Int. J Gynecol. Cancer 2003;13:241-250.
7. Sugarbaker PH: Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998;14:254-261.
8. Hoskins WJ: The influence of the cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:59-71.
9. Hoskins WJ, McGuire WP, Homesley HD, et al.: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-980.
10. Barakat RR, Sabbatini P, Bhaskaran D, et al.: Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up. J Clin Oncol 2002;20:694-698.
11. Sugarbaker PH: Complete parietal and visceral peritonectomy of the pelvis for avanced primary and recurrent ovarian cancer. Cancer Treat Res 1996;81:75-87.
12. Carmignani CP, Sugarbaker PH: Comprehensive approach to advanced primary and recurrent ovarian cancer, a personal experience. Expert Rev Anticancer Ther 2004;4:477-487.
13. Gilly FN, Beaujard A, Glehen O, et al.: Peritonectomy combined with intraperitoneal chemohyperthermia in abdominal cancer with peritoneal carcinomatosis: Phase I-II study. Anticancer Res 1999;19:2317-2321.
14. Begossi G, Gonzalez-Moreno S, Ortega-Perez G, et al.: Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma. Eur J Surg Oncol 2002;28:80-87.
15. Deraco M, Rossi CR, Pennacchioli E, et al.: Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: A phase II clinical study. Tumori 2001;87:120-126.
16. Alberts DS, Liu PY, Hannigan EV, et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-1955.
17. Markman M, Bundy BN, Alberts DS, et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001-1007.
18. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
19. Hogberg T, Glimelius B, Nygren P, et al.: Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol 2001;40:340-360.
20. Herrin VE, Thigpen JT: Chemotherapy for ovarian cancer: Current concepts. Semin Surg Oncol 1999;17:181-188.
21. Mekhail TM, Markman M: Paclitaxel in cancer therapy. Expert Opin Pharmacother 2002;3:755-766.
22. Markman M, Rowinsky E, Hakes T, et al.: Phase 1 trial of intraperitoneal taxol: A Gynecologic Oncology Group study. J Clin Oncol 1992;10:1485-1491.
23. Francis P, Rowinsky E, Schneider J, et al.: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: A Gynecologic Oncology Group pilot study. J Clin Oncol 1995;13:2961-2967.
24. Piso P, Dahlke MH, Loss M, et al.: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2004;2:21.
25. Zanon C, Clara R, Chiappino I, et al.: Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004;28:1040-1045.
26. Jacquet P, Stephens AD, Averbach AM, et al.: Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77:2622-2629.
27. Stephens AD, Alderman R, Chang D, et al.: Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790-796.
28. Ansquer Y, Leblanc E, Clough K, et al.: Neoadjuvant chemotherapy for unresectable ovarian carcinoma: A French multicenter study. Cancer 2001;91:2329-2334.
29. Kuhn W, Rutke S, Spathe K, et al.; Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIc ovarian carcinoma. Cancer 2001;92:2585-2591.
30. Jacob JH, Gershenson DM, Morris M, et al.: Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer. Gynecol Oncol 1991;42:146-150.
31. Kayikcioglu F, Kose MF, Boran N, et al.: Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer. 2001;11:466-470.
32. McCreath WA, Chi DS: Surgical cytoreduction in ovarian cancer. Oncology (Huntingt) 2004;18:645-653.